CD40L-GVAX

N/A

Report date: 2022/07/20 10:11:27

Base Information

Drug NameCD40L-GVAX
Drug Alias NameGM.CD40L bystander vaccineBystander vaccineBystander-based autologous tumour cell vaccineAutologous tumour cell-based vaccineCD40L-GVAX +[8] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulantsTumor necrosis factor receptor superfamily member 5 agonists
TargetsGranulocyte-macrophage colony-stimulating factor receptorTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSkin MelanomaMyelodysplastic SyndromesLung Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesUniversity Of South Florida
China Registration ClassN/A

Develop Information

Active CompaniesBlackbird Bio FinanceCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesH Lee Moffitt Cancer Center & Research Institute
Active IndicationsLung NeoplasmsMelanoma
Inactive IndicationsSkin MelanomaMyelodysplastic SyndromesAdenocarcinoma of Lung +[5] 

Other Information

ATC CodeN/A
Related LinksN/A